Radient Technologies Inc V.RTI.H

Canopy is opportunistic and greedy

[lscfa]

Co. should focus on selling product.

It can be argued that infringing an extraction patent simply makes the input costs of an finished product a bit cheaper and the patent holder is entitled at most to the savings in production costs and not a share of  sales of the finished product.  As drugs have large markups the inputs costs are likely to be a small fraction of the selling price.